Our Keynote lung cancer clinical trials are studying pembrolizumab to see if it may help patients with lung cancer. Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
Keynote clinical trials are currently enrolling patients with non-small cell and small cell lung cancer. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer||598||Carcinoma, Non-Small-Cell Lung||Phase 3||Recruiting|
|A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer||407||Non-small Cell Lung Cancer||Phase 3||Recruiting|
|Efficacy and Safety of Pembrolizumab With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer||671||Non-small Cell Lung Cancer||Phase 3||Recruiting|
|Study of Pembrolizumab in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma||001||Cancer, Solid Tumor||Phase 1||Active, not recruiting|
|Study of Two Doses of Pembrolizumab Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer||010||Non Small Cell Lung Cancer (NSCLC)||Phase 2/Phase 3||Active, not recruiting|
|Study of Pembrolizumab Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer||011||
||Phase 1||Active, not recruiting|
|A Study of Pembrolizumab in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer||021||Non-small Cell Lung Carcinoma||Phase 1/Phase 2||Active, not recruiting|
|Study of Pembrolizumab Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer||024||Non-Small Cell Lung Carcinoma||Phase 3||Active, not recruiting|
|Study of Pembrolizumab in Participants With Advanced Non-small Cell Lung Cancer||025||Non-small Cell Lung Cancer||Phase 1||Completed|
|Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab in Chinese Participants With Non-Small-Cell Lung Cancer||032||Non-Small-Cell Lung Cancer||Phase 1||Active, not recruiting|
|Study of MK-3475 Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer||042||Non-small Cell Lung Cancer||Phase 3||Active, not recruiting|
|Study of Pembrolizumab vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy||091||Non-small Cell Lung Cancer||Phase 3||Recruiting|
|Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer||189||Non-Small-Cell Lung Carcinoma||Phase 3||Active, not recruiting|
|A Study of Pembrolizumab in Combination With Etoposide/Platinum for Participants With Extensive Stage Small Cell Lung Cancer||604||